Zusammenfassung
Die Krankheitsdynamik maligner Schilddrüsentumoren variiert stark. Daher kann die palliative Phase unterschiedlich lang sein. So entsteht ein Patientenkollektiv, das zwar nicht mehr kurativ behandelt werden kann, aber unter palliativer Therapie eine respektable Lebenserwartung hat. Therapeutisches Vorgehen sowie die Einschätzung der palliativen Situation hängen stark vom vorliegenden Tumortyp ab. Die moderne Onkologie bietet neben den klassischen Therapieformen, bestehend aus chirurgischer Resektion mit anschließender Radiojodtherapie, weitere Optionen, wie Therapie mit Tyrosinkinaseinhibitoren bei entstandener Jodresistenz, an. Bei Beteiligung umliegender Organe treten frühzeitig Beeinträchtigungen wichtiger Lebensfunktionen auf. Drohender Autonomieverlust und Versorgungsbedürftigkeit der Patienten können präventive palliativchirurgische Maßnahmen notwendig machen, um die Lebensqualität der Patienten zu unterstützen. Art und Umfang chirurgischer Maßnahmen in dieser Grenzzone ist bei den verschiedenen Formen des Schilddrüsenkarzinoms unterschiedlich zu bewerten.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Agrawal N et al (2017) Indications and extent of central neck dissection for papillary thyroid cancer: an American head and neck society consensus statement. Head Neck 39(7):1269–1279
Ahmadi S et al (2016) Hürthle cell carcinoma: current perspectives. Onco Targets Ther 9:6873–6884
Ahmend et al (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 165:315–322
Brose MS et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced, double-blind, phase 3 trial. Lancet 384(9940):319–328
Cabanillas ME et al (2016a) Thyroid cancer. Lancet 388(10061):2783–2795
Cabanillas ME et al (2016b) Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J Oncol Pract 12(6):511–519
Chintakuntlawar AV et al (2017) Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab 102(6):1943–1950
Copland JA et al (2006) Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25:2304–2317
Dralle H (2014) Endokrine Chirurgie. Evidenz und Erfahrung – Individualisierte Medizin in der klinischen Praxis. Schattauer, Stuttgart
Dralle H et al (2013) German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg 398(3):403–409
Durante C et al (2006) Long-term outcome of 444 patients with distant metastases from papillary and folliculary thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91(8):2892–2899
Elisei R et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639–3646
Ernani V et al (2016) Systemic treatment and management approaches for medullary thyroid cancer. Cancer Treat Rev 50:89–98
Fialkowsky E et al (2008) Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32:754–765
Gibson W et al (2017) Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer. Clin Cancer Res 23(9):2367–2373
Haigh PI et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irridation is associated with prolonged survival. Cancer 91(12):2335–2342
Haugen BR et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133
Higashiyama T et al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20(1):7–14
Ito Y et al (2017a) Prognostic significance of the proportion of all cell components in papillary thyroid carcinoma. World J Surg 41:742–747
Ito Y et al (2017b) Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and Anaplastic thyroid carcinoma. Thyroid 27(9):1142–1148
Jin LX et al (2016) Surgery for lymph node metastases of medullary thyroid carcinoma: a review. Cancer 122(3):358–366
Kebebew E et al (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7):1330–1335
Keutgen XM et al (2015) Management of anaplastic thyroid cancer. Gland Surg 4(1):44–51
Kim BH et al (2016) Recent updates on the management of medullary thyroid carcinoma. Endocrinol Metab (Seoul) 31(3):392–399
Kim SW et al (2017) Intraoperative real-time localization of parathyroid gland with near infrared fluorescence imaging. Gland Surg 6(5):516–524
Lavazza M et al (2016) Indocaynine green-enhanced fluorescence for assessing parathyroid perfusion during thyroidectomy. Gland Surg 5(5):512–521
Leite AK et al (2017) Death related to pulmonary metastasis in patients with differentiated thyroid cancer. Endocr Pract 23(1):72–78
Li F et al (2015) BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer 22(2):159–168
Lim SM et al (2013) A multicenter phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 24(12):3089–3094
Liu et al (2014) TERT promoter mutations and their associations with BRAFV600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99(6):1130–1136
Lorusso L et al (2016) Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced and progressive thyroid cancer. Onco Targets Ther 9:6467–6477
Lubitz CC et al (2014) Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid 24(6):958–965
Mazzaferri EL et al (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97(5):418–428
Meijer JA et al (2010) Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol 72:534–542
Mitchell AL et al (2016) Management of thyroid cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol 130(S2):S150–S160
Molinaro E et al (2017) Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nature Rev, advanced online publication. https://doi.org/10.1038/nrendo.2017.76
Nixon IJ et al (2012) The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 22:884–889
Onoda N et al (2016) The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid 26(9):1293–1299
Pantvaidya G et al (2017) Morbidity of central compartment clearance: comparison of lesser versus complete clearance in patients with thyroid cancer. J Cancer Res Ther 13(1):102–106
Perri F et al (2011) Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2(3):150–157
Poisson T et al (2010) 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 37:2277–2285
Porterfield JR et al (2009) Thoracic metastasectomy for thyroid malignancies. Eur J Cardiothorac Surg 36(1):155–158
Prasongsook N et al (2017) Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab 102(12):4506–4514
Pusztaszeri M et al (2017) Update on the cytologic features of papillary thyroid carcinoma variants. Diagn Cytopathol 45(8):714–730
Randle RW et al (2017) Trends in the presentation, treatment and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 161(1):137–146
Robenshtok E et al (2012) Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 97(8):2706–2713
Roh JL et al (2011) Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. Ann Surg Oncol 18:1312–1318
Rondeau G, Fish S, Hann LE et al (2011) Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid 21:845–853
Rosove MH et al (2013) BRAF V600E inhibition in anaplastic thyroid cancer. NEJM 368(7):684–685
Sabra MM et al (2013) Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endicrinol Metab 98(5):E829–E836
Schlumberger M et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. NEJM 372(7):621–630
Schmid KW et al (2015) Lymphknoten- und Organmetastasen des Schilddrüsenkarzinoms. Pathologe 36:171–175
Shaha AR et al (1997) Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174:474–476
Shen X et al (2017) A six-genotype genetic prognostic model for papillary thyroid cancer. Endocr Relat Cancer 24(1):41–52
Shi X et al (2016) Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab 101(1):264–274
Shin DH et al (1993) Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection. Hum Pathol 24:866–870
Shirley LA et al (2017) The role of central neck lymph node dissection in the management of papillary thyroid cancer. Front Oncol 7(122):1–7
Sk2-Leitlinie zur operativen Therapie maligner Schilddrüsenerkrankungen (2012). https://www.dgav.de/fileadmin/media/texte_pdf/caek/Leitlinie_Maligne_Schilddruesenerkrankungen_Operative_Therapie_2012-11.pdf. Zugegriffen am 27.11.2018
Smallridge RC et al (2013) Efatutazone, an oral PPRAGamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab 98(6):2392 ff
Sound S et al (2015) Utility of indocyanine green fluorescence imaging for intraoperative localization in reoperative parathyroid surgery. Surg Innov Oct:1–6
Su SY et al (2016) Well-differentiated thyroid cancer with aerodigestive tract invasion: long-term control and functional outcomes. Head Neck 38(1):72–78
Su A et al (2018) Effect of autotransplantation of a parathyroid gland on hypoparathyroidism after total thyroidectomy. Endocr Connect 7(2):286–294
Tiedje V et al (2017) NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget 8(26):42613–42620
Wagle N et al (2014) Response and acquired resistance to everolimus in anaplastic thyroid cancer. NEJM 371(15):1426–1433
Wang LY et al (2016) Operative management of locally advanced, differentiated thyroid cancer. Surgery 160(3):738–746
Wells SA et al (2012) Vandetanib inpatients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134–141
Wells SA et al (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610
Wendler J et al (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: a result of a multicenter study in Germany. Eur J Endocrinol 175:521–529
Xu et al (2016a) Clinicopathologic features of fatal non-anaplastic follicular cell-derived thyroid carcinomas. Thyroid 26(11):1588–1597
Xu JY et al (2016b) Bone metastases and skeletal-related events in medullary thyroid carcinoma. J Clin Endocrinol Metab 101(12):4871–4877
Xu B et al (2016c) Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol 27:205–2012
Yang Z et al (2017a) Comparison of survival outcomes following postsurgical radioactive iodine versus external beam radiation in stage IV differentiated thyroid carcinoma. Thyroid 27(7):944–952
Yang X et al (2017b) TERT Promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J Nucl Med 58(2):258–265
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Kühn, P. (2019). Palliative Chirurgie maligner Schilddrüsentumoren. In: Ghadimi, M., Homayounfar, K., Kalff, J. (eds) Palliative Viszeralchirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57362-4_22
Download citation
DOI: https://doi.org/10.1007/978-3-662-57362-4_22
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57361-7
Online ISBN: 978-3-662-57362-4
eBook Packages: Medicine (German Language)